NEW YORK, Dec. 22, 2020 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Bayerische Motoren Werke AG (OTC: BMWYY, BAMXF)
Class Period: November 3, 2015 – September 24, 2020
Deadline: December 28, 2020
For more info: www.bgandg.com/bmwyy
The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and specifically failed to disclose that: (1) BMW kept a “bank” of retail vehicle sales that it used to meet internal monthly sales targets regardless of when the sales actually occurred; (2) BMW artificially manipulated sales figures by having dealers register cars as sold when the cars were still in inventory; (3) as a result, BMW’s key operating metrics were inaccurate and misleading; and (4) as a result, defendants’ statements about BMW’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Zosano Pharma Corporation (NASDAQ: ZSAN)
Class Period: February 13, 2017 – September 30, 2020
Deadline: December 28, 2020
For more info: www.bgandg.com/zsan
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company’s New Drug Application (“NDA”) included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, defendants’ public statements were materially false and misleading at all relevant times.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
- Paycor Announces Upsize and Pricing of Offering of Common Stock by Selling Stockholders - December 2, 2022
- springbig Honored at 2022 South Florida Business Journal Miami Inno Fire Awards - December 2, 2022
- Anti-Static Films Market Size to Surpass USD 767.66 Million by 2030 at 4.57% CAGR – Report by Market Research Future (MRFR) - December 2, 2022